CYP2C19 loss-of-function carriers have increased risk of cardiac, but not limb, events following clopidogrel treatment for peripheral artery disease revascularization
Authors:
- Sharon E. KimSKSharon E. Kim
- Katherine M. ReitzKRKatherine M. Reitz
- Mary Ann OstachMOMary Ann Ostach
- Marissa JarosinskiMJMarissa Jarosinski
- Olivia RomanoOROlivia Romano
- Kyle MarkelKMKyle Markel
- Philip E. EmpeyPEPhilip E. Empey
- Edith TzengETEdith Tzeng
Open Access
- 10 August 2026
- journal article
- Published by Elsevier in JVS-Vascular Insights
- Vol. 4
Abstract
No abstract availableFunding Information
- National Heart, Lung, and Blood Institute (T32 HL098036)
- Office of Research, Health Sciences, University of Pittsburgh
- University of Pittsburgh
- Clinical and Translational Science Institute, University of Pittsburgh
This publication has 40 references indexed in Scilit:
- Drug-Gene Interactions and Clinical Outcomes After Vascular Surgery in the Million Veteran ProgramJAMA Surgery, 2025
- Association Between Time to Source Control in Sepsis and 90-Day MortalityJAMA Surgery, 2022
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 UpdateClinical Pharmacology & Therapeutics, 2022
- STROBE Reporting Guidelines for Observational StudiesJAMA Surgery, 2021
- Association Between Preoperative Metformin Exposure and Postoperative Outcomes in Adults With Type 2 DiabetesJAMA Surgery, 2020
- Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics ConsortiumClinical Pharmacology & Therapeutics, 2020
- P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary SyndromesJAMA Cardiology, 2019
- Assessment of ICD‐10‐CM code assignment validity for case finding of outpatient anticoagulant‐related bleeding among Medicare beneficiariesPharmacoepidemiology and Drug Safety, 2019
- Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet TherapyClinical Pharmacology & Therapeutics, 2017
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010